CTLA-4-directed Antibody Interactions [MoA] - N0000182634

Name: Table of NDC products with ctla-4-directed antibody interactions
Creator: U.S. Food & Drug Administration
License: https://creativecommons.org/licenses/by-nc-sa/4.0/

Pharmacologic Class Information

Pharmacologic Code	N0000182634
Pharmacologic Name	CTLA-4-directed Antibody Interactions
Pharmacologic Uses	human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody
Pharmacologic Concept	Mechanisms of Action - [MoA]
Pharmacologic Concept Description	This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

NDC Products with CTLA-4-directed Antibody Interactions

The table contains 2 products whose active ingredient are classified under the same pharmacologic class CTLA-4-directed Antibody Interactions [MoA].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	0003-2327	Yervoy	Non-Proprietary Name: Ipilimumab	Injection	Intravenous	E.r. Squibb & Sons, L.l.c.	ACTIVE
	0003-2328	Yervoy	Non-Proprietary Name: Ipilimumab	Injection	Intravenous	E.r. Squibb & Sons, L.l.c.	ACTIVE